http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AbbVie to Present at Citi's 2024 Global Healthcare Conference
-
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
-
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
-
AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
-
AbbVie (ABBV) Phase 2 Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint
-
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
-
Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
-
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
-
AbbVie (ABBV), EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
-
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
-
AbbVie Reports Third-Quarter 2024 Financial Results
-
SkinSpirit joins Allergan Aesthetics in Supporting Girls Inc. and Empowering the New Generation of Women in STEM
-
AbbVie (ABBV) Acquires Aliada Therapeutics
-
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
-
AbbVie (ABBV) and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
-
AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
-
BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
-
AbbVie (ABBV): U.S. FDA Approves VYALEV for Adults Living with Advanced Parkinson's Disease
-
U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease
-
Allergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception
-
Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM
-
Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
-
AbbVie to Host Third-Quarter 2024 Earnings Conference Call
-
AbbVie (ABBV) Submits Biologics License Application to the FDA for Telisotuzumab Vedotin
-
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
-
AbbVie (ABBV) Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
-
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
-
AbbVie (ABBV): New Analysis Demonstrates the Efficacy of RINVOQ in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
-
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
-
Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns
-
AbbVie (ABBV) Receives Positive CHMP Opinion for Mirvetuximab Soravtansine for the Treatment of Certain Adult Ovarian Cancer
-
AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
-
AbbVie's (ABBV) Allergan Aesthetics Launches BOTOX Cosmetic for Masseter Muscle Prominence in Adults in China
-
Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China
-
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
-
AbbVie Declares Quarterly Dividend
-
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
-
AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
-
AbbVie (ABBV): SkinMedica Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
-
SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
-
AbbVie (ABBV): EC Grants Second Indication Approval for TEPKINLY for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
-
European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
-
AbbVie (ABBV) Completes Acquisition of Cerevel Therapeutics
-
AbbVie Completes Acquisition of Cerevel Therapeutics
-
Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day
-
AbbVie (ABBV) Announces European Commission Approval of SKYRIZI for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
-
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
-
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
-
AbbVie Reports Second-Quarter 2024 Financial Results
-
AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for Upadacitinib in Giant Cell Arteritis
